Resistance & Activating Mutations Diagnosed Among NSCLC Community Dwelling EGFR Mutation Positive Patients - RADIANCE

Study identifier:D5160L00032

ClinicalTrials.gov identifier:NCT03137264

EudraCT identifier:N/A

CTIS identifier:N/A

Study Complete

Official Title

An Open-Label, Non-randomized, Prospective Biomarker Study to Assess Analytic Concordance Between Non-invasive Testing and Tissue Testing for EGFR T790M Mutation Detection in Patients with Non-small Cell Lung Cancer

Medical condition

Non-small Cell Lung Cancer

Phase

Phase 4

Healthy volunteers

No

Study drug

Other

Sex

All

Actual Enrollment

44

Study type

Observational

Age

18 Years - 130 Years

Date

Study Start Date: 24 Oct 2017
Primary Completion Date: 10 Nov 2018
Study Completion Date: 10 Nov 2018

Study design

Allocation: N/A
Endpoint Classification: -
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Diagnostic

Verification:

Verified 01 Nov 2019 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

Medpace

Inclusion and exclusion criteria